Serious adverse reactions in a tuberculosis programme setting in Kyrgyzstan.
Serious adverse reactions among new smear-positive patients were studied in a programme setting in Kyrgyzstan. Two per cent of patients on tuberculosis (TB) treatment had to interrupt treatment for > or =1 week, and more than 80% of the reactions occurred during the first month of treatment. Pyrazinamide was the most common causative agent, followed by rifampicin.
Hinderaker
S G
SG
Centre for International Health, University of Bergen, Bergen, Norway. Sven.Hinderaker@cih.uib.no
Ysykeeva
J
J
Veen
J
J
Enarson
D A
DA
D000328:Adult; D000995:Antitubercular Agents / Q000009:adverse effects* / Q000627:therapeutic use; D003140:Communicable Disease Control / Q000379:methods; D006801:Humans; D007707:Kyrgyzstan / Q000453:epidemiology; D011718:Pyrazinamide / Q000009:adverse effects / Q000627:therapeutic use; D012293:Rifampin / Q000009:adverse effects / Q000627:therapeutic use; D013183:Sputum / Q000382:microbiology; D014376:Tuberculosis / Q000188:drug therapy*
D000995:Antitubercular Agents; D011718:Pyrazinamide; D012293:Rifampin